Please assess the completion status of the following clinical trial:

Trial Title: Dose Response Study of Nitisinone in Alkaptonuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria~A subject must fulfil the following criteria in order to be included in the study:~1. Diagnosis of alkaptonuria verified by documented elevated urinary homogentisic acid excretion.~2. Age ≥18 years.~3. Willing and able to visit the investigational site for study visits.~4. Signed written informed consent obtained.~Exclusion criteria~The presence of any of the following will exclude a subject from inclusion in the study:~1. Non-alkaptonuria causes of ochronosis.~2. Currently pregnant or lactating.~3. Known allergy to nitisinone or any of the constituents of the investigational product.~4. Use of a protein-restricted diet~5. Dietary habits or use of homeopathic therapies that interfere with tyrosine catabolism.~6. Current keratopathy, contact lens use or uncontrolled glaucoma.~7. Current malignancy.~8. Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than 95 diastolic).~9. Electrocardiogram changes indicative of myocardial infarction, arrhythmia, tachycardia, bradycardia, left bundle branch block.~10. Chest radiographic abnormalities, including an infiltrative, mass, congestive heart failure, embolism, atelectasis.~11. Serum potassium \< 3.0 mmol/L.~12. eGFR \< 60 mL/min.~13. Any hepatic enzymes greater than 3 x upper limit of normal.~14. Haemoglobin \< 10.0 g/dL.~15. Platelets less than 100 x 109/L.~16. WBC less than 3.0 x 109/L.~17. ESR greater than 100 mm/h.~18. History of alcohol or drug abuse.~19. Participation in another clinical trial within 3 months of randomisation.~20. Treatment with nitisinone within 3 months of randomisation~21. Psychiatric illness or neurological disease that interferes with compliance or communication with health care personnel.~22. Any other medical condition which in the opinion of the investigator makes the subject unsuitable for inclusion.~23. Foreseeable inability to cooperate with given instructions or study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- no treatment (Type: NO_INTERVENTION): comparrator
- Nitisinone 1mg (Type: EXPERIMENTAL): interventional
- Nitisinone 2mg (Type: EXPERIMENTAL): interventional
- Nitisinone 4mg (Type: EXPERIMENTAL): interventional
- Nitisinone 8mg (Type: EXPERIMENTAL): interventional

Based on this trial design, predict the completion outcome and termination type (if applicable).